- Home
- BLND vs MREO Comparison
BLND vs MREO Comparison
Compare BLND & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLND
- MREO
- Stock Information
- Founded
- BLND 2012
- MREO 2015
- Country
- BLND United States
- MREO United Kingdom
- Employees
- BLND N/A
- MREO N/A
- Industry
- BLND EDP Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- BLND Technology
- MREO Health Care
- Exchange
- BLND Nasdaq
- MREO Nasdaq
- Market Cap
- BLND 625.9M
- MREO 577.6M
- IPO Year
- BLND 2021
- MREO N/A
- Fundamental
- Price
- BLND $3.33
- MREO $4.53
- Analyst Decision
- BLND Buy
- MREO Strong Buy
- Analyst Count
- BLND 6
- MREO 4
- Target Price
- BLND $3.58
- MREO $7.50
- AVG Volume (30 Days)
- BLND 1.6M
- MREO 601.5K
- Earning Date
- BLND 11-05-2024
- MREO 11-13-2024
- Dividend Yield
- BLND N/A
- MREO N/A
- EPS Growth
- BLND N/A
- MREO N/A
- EPS
- BLND N/A
- MREO N/A
- Revenue
- BLND $152,122,000.00
- MREO $1,000,000.00
- Revenue This Year
- BLND $4.74
- MREO $16.39
- Revenue Next Year
- BLND $25.20
- MREO $9.44
- P/E Ratio
- BLND N/A
- MREO N/A
- Revenue Growth
- BLND N/A
- MREO N/A
- 52 Week Low
- BLND $1.15
- MREO $1.59
- 52 Week High
- BLND $4.25
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- BLND 39.51
- MREO 57.36
- Support Level
- BLND $3.38
- MREO $4.42
- Resistance Level
- BLND $3.97
- MREO $4.50
- Average True Range (ATR)
- BLND 0.19
- MREO 0.20
- MACD
- BLND -0.03
- MREO 0.04
- Stochastic Oscillator
- BLND 0.77
- MREO 70.77
About BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).